Intramyocardial and intracoronary autologous bone marrow-derived mesenchymal stromal cell treatment in chronic severe dilated cardiomyopathy

References

• Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, . Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26:1115–40.
   PubMed Web of Science ®Google Scholar
• Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, . Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347: 1397–402.
   PubMed Web of Science ®Google Scholar
• Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation. 2005;111:2837–49.
   PubMed Web of Science ®Google Scholar
• Bax JJ, Visser FC, Poldermans D, Elhendy A, Cornel JH, Boersma E, . Relationship between preoperative viability and postoperative improvement in LVEF and heart failure symptoms. J Nucl Med. 2001;42:79–86.
   Google Scholar
• Lipiecki J, Durel N, Ponsonnaille J. Which patients with ischemic heart disease could benefit from cell replacement therapy? Eur Heart J. 2006;8(Suppl H):H3–7.
   Google Scholar
• Boyle AJ, Schulman SP, Hare JM, Oettgen P. Stem cell therapy for cardiac repair: ready for the next step. Circulation. 2006;114:339–52.
   PubMed Web of Science ®Google Scholar
• Abdel-Latif A, Bolli R, Tleyjeh IM, Montori VM, Perin EC, Hornung CA, . Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med. 2007;167:989–97.
   PubMed Web of Science ®Google Scholar
• Lipinski MJ, Biondi-Zoccai GG, Abbate A, Khianey R, Sheiban I, Bartunek J, . A collaborative systematic review and meta-analysis of controlled clinical trials. J Am Coll Cardiol. 2007;50:1761–7.
   PubMed Web of Science ®Google Scholar
• Janssens S, Dubois C, Bogaert J, Theunissen K, Deroose C, Desmet W, . Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet. 2006;367:113–21.
   PubMed Web of Science ®Google Scholar
• Meyer GP, Wollert KC, Lotz J, Steffens J, Lippolt P, Fichtner S, . Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months’ follow-up data from the randomized, controlled BOOST (BOnemarrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation. 2006;113:1287–94.
   PubMed Web of Science ®Google Scholar
• Chen SL, Fang WW, Ye F, Liu YH, Qian J, Shan SJ, . Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol. 2004;94:92–5.
   PubMed Web of Science ®Google Scholar
• Katritsis DG, Sotiropoulou PA, Karvouni E, Karabinos I, Korovesis S, Perez SA, . Transcoronary transplantation of autologous mesenchymal stem cells and endothelial progenitors into infarcted human myocardium. Catheter Cardiovasc Interv. 2005;65:321–9.
   PubMed Web of Science ®Google Scholar
• Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation. 2002; 105:93–8.
   PubMed Web of Science ®Google Scholar
• Ghannam S, Bouffi C, Djouad F, Jorgensen C, Noel D. Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications. Stem Cell Res Ther. 2010;1:2 doi:10.1186/scrt2.
   PubMed Web of Science ®Google Scholar
• Guarita-Souza CL, de Carvalho KAT, Francisco JC, Simeoni R, Faria-Neto JR, Cellular transplantation for the treatment of non-ischaemic dilated cardiomyopathies. Eur Heart J Suppl. 2008;10:K7–10.
   Google Scholar
• Chin SP, Poey AC, Wong CY, Chang SK, Teh W, Mohr TJ, . Cryopreserved mesenchymal stromal cell treatment is safe and feasible for severe dilated ischemic cardiomyopathy. Cytotherapy. 2010;12:31–7.
   PubMed Web of Science ®Google Scholar
• Wong CY, Cheong SK, Mok PL, Leong CF. Differentiation of human mesenchymal stem cells into mesangial cells in post-glomerular injury murine model. Pathology. 2008;40: 52–7.
   PubMed Web of Science ®Google Scholar
• Law PK, Chin SP, Hung HD, Nguyen TN, Feng QZ. Delivery of biologics for angiogenesis and myogenesis. Nguyen TN, Colombo A, Hu D, Grines CL, Saito S. Practical Handbook of Advanced Interventional Cardiology. 3rd. New York: Blackwell; 2008. 583–95.
   Google Scholar
• Sherman W, Martens TP, Viles-Gonzalez JF, Siminiak T. Catheter-based delivery of cells to the heart. Nat Clin Pract Cardiovasc Med. 2006;3(Suppl 1):S57–64.
   Google Scholar
• Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EG, Willemze R, Fibbe WE. Donor derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood. 2006;108:2114–20.
   PubMed Web of Science ®Google Scholar
• Perin EC, Dohmann HF, Borojevic R, Silva SA, Sousa AL, Mesquita CT, . Transendocardial autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation. 2003;107:2294–302.
   PubMed Web of Science ®Google Scholar
• Assmus B, Honold J, Schächinger V, Britten MB, Fischer-Rasokat U, Lehmann R, . Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med. 2006;355:1222–32.
   PubMed Web of Science ®Google Scholar
• Bax JJ, Poldermans D, Elhendy A, Cornel JH, Boersma E, Rambaldi R, . Improvement of left ventricular ejection fraction, heart failure symptoms and prognosis after revascularization in patients with chronic coronary artery disease and viable myocardium detected by dobutamine stress echocardiography. J Am Coll Cardiol. 1999;34:163–9.
   PubMed Web of Science ®Google Scholar
• Schinkel AF, Poldermans D, Rizzello V, Vanoverschelde JL, Elhendy A, Boersma E, . Why do patients with ischaemic cardiomyopathy and a substantial amount of viable myocardium not always recover in function after revascularization? J Thorac Cardiovasc Surg. 2004;127:385–90.
   Google Scholar
• Bax JJ, Schinkel AF, Boersma E, Elhendy A, Rizzello V, Maat A, . Extensive left ventricular remodeling does not allow viable myocardium to improve in left ventricular ejection fraction after revascularization and is associated with worse long-term prognosis. Circulation. 2004;110:II18–22.
   PubMed Web of Science ®Google Scholar
• Dimmeler S, Zeiher AM, Schneider MD. Unchain my heart: the scientific foundations of cardiac repair. J Clin Invest. 2005;115:572–83.
   PubMed Web of Science ®Google Scholar
• Chen S, Liu Z, Tian N, Zhang J, Yei F, Duan B, . Intracoronary transplantation of autologous bone marrow mesenchymal stem cells for ischemic cardiomyopathy due to isolated chronic occluded left anterior descending artery. J Invasive Cardiol. 2006;18:552–6.
   PubMedGoogle Scholar
• Gao LR, Wang ZG, Zhu ZM, Fei YX, He S, Tian HT, . Effect of intracoronary transplantation of autologous bone marrow-derived mononuclear cells on outcomes of patients with refractory chronic heart failure secondary to ischemic cardiomyopathy. Am J Cardiol. 2006;98:597–602.
   PubMed Web of Science ®Google Scholar